GO:0007250 activation of NF-kappaB-inducing kinase activity: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007250 describes the biological process that turns on the kinase activity of NF-kappaB-inducing kinase (NIK, gene symbol MAP3K14), the central kinase of the non-canonical NF-kappaB pathway.
• NIK activation is normally held in check by a TRAF3-TRAF2-cIAP1/2 degradation complex; receptor signals such as LTbetaR, BAFF-R, CD40 and RANK allow NIK to accumulate and become active.
• Once active, NIK phosphorylates IKKalpha, which in turn processes p100 (NFKB2) into p52, releasing RelB-p52 dimers that drive target gene transcription.
• Deregulated NIK activity is implicated in cancer, diabetes, insulin resistance, amyotrophic lateral sclerosis and soft tissue sarcoma [2,4,5,6,7].
• NIK also controls mitochondrial respiratory capacity and metabolic fitness of immune cells, linking GO:0007250 to immunometabolism [3,8].
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential tools for dissecting NIK activation in disease contexts [2,4,7].
Description
GO:0007250, activation of NF-kappaB-inducing kinase activity, is a biological process that converts NF-kappaB-inducing kinase (NIK, encoded by MAP3K14) from a constitutively degraded, largely inactive state into an active serine/threonine kinase capable of propagating non-canonical NF-kappaB signaling. NIK is the pivotal MAP3K of this pathway, and its activation is the rate-limiting step that licenses downstream IKKalpha-mediated processing of p100 to p52 and nuclear accumulation of RelB-containing dimers. Because NIK activity is tightly controlled at the level of protein stability, the term captures not merely a catalytic event but the entire regulatory transition that allows NIK to accumulate and phosphorylate its substrates. Researchers care about GO:0007250 because inappropriate NIK activation is a driver or modifier of multiple human diseases. Constitutive NIK activity in the mesenchymal lineage causes spontaneous soft tissue sarcoma in mice, and NIK is broadly implicated in cancer biology. In pancreatic islet beta cells, forced NIK activation precipitates beta cell failure and diabetes, while NIK provokes insulin resistance in skeletal muscle of obese mice. Inhibiting NIK improves motor performance in an ALS animal model, and NIK maintains T cell metabolic fitness during antitumor immunity. NIK also governs mitochondrial respiratory capacity and the inflammatory status of innate immune cells. Understanding GO:0007250 therefore requires integrating receptor-proximal signals, ubiquitin-dependent degradation of NIK, catalytic activation, substrate selection and downstream transcriptional outputs. This article summarizes the authoritative ontology annotation, the molecular mechanism, the key genes involved, disease links and the CRISPR-based research methods used to study NIK activation.
activation of NF-kappaB-inducing kinase activity At A Glance
| GO ID | GO:0007250 |
|---|---|
| GO term | activation of NF-kappaB-inducing kinase activity |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Turning on NIK (MAP3K14) kinase activity to initiate non-canonical NF-kappaB signaling |
| Key kinase | NIK / MAP3K14 |
| Upstream regulators | TRAF3, TRAF2, cIAP1/2, LTbetaR, BAFF-R, CD40, RANK |
| Downstream substrate | IKKalpha (CHUK), leading to p100 processing |
| Pathway context | Non-canonical NF-kappaB signaling |
What Is GO:0007250?
GO:0007250 (activation of NF-kappaB-inducing kinase activity) is the biological process in which the kinase activity of NF-kappaB-inducing kinase (NIK, MAP3K14) is switched on. In the non-canonical NF-kappaB pathway, NIK is normally kept at low levels by a TRAF3-TRAF2-cIAP1/2 ubiquitin ligase complex that targets it for degradation; receptor engagement disrupts this complex, allowing NIK to accumulate and become catalytically active. The activated kinase then phosphorylates IKKalpha, triggering p100 processing to p52 and RelB-p52 nuclear translocation. Thus, the term denotes the regulated transition from a NIK-off state to a NIK-on state, rather than a static molecular function.
Why Is activation of NF-kappaB-inducing kinase activity Important in Cell Biology?
GO:0007250 is important because NIK activation is the committed, rate-limiting step of non-canonical NF-kappaB signaling, a pathway that controls lymphoid organogenesis, B cell survival, bone homeostasis and immune cell metabolism. When this step is deregulated, the consequences are severe: constitutive NIK activity drives soft tissue sarcoma, contributes to cancer progression, causes beta cell failure and diabetes, provokes insulin resistance in skeletal muscle, worsens motor performance in ALS models, and alters mitochondrial respiratory capacity and inflammatory status of innate immune cells. Because NIK activation is controlled by ubiquitin-dependent degradation, it is also a highly druggable node, making GO:0007250 a central focus for both mechanistic immunology and therapeutic development [1,2].
• Defines the rate-limiting activation step of non-canonical NF-kappaB signaling.
• Controls p100 processing to p52 and RelB-p52 transcriptional activity.
• Deregulated NIK activation is oncogenic and drives soft tissue sarcoma in mouse models.
• NIK activation in islet beta cells causes beta cell failure and diabetes.
• NIK activation in skeletal muscle contributes to insulin resistance in obesity.
• Inhibiting NIK activity improves motor performance in an ALS animal model.
• NIK activation supports T cell metabolic fitness in antitumor immunity.
• NIK governs mitochondrial respiratory capacity and inflammatory status of innate immune cells.
• NIK is a candidate therapeutic target across cancer and metabolic disease.
• The process is experimentally tractable with CRISPR KO, point-mutation, knock-in and overexpression models [2,4,7].
What Happens During activation of NF-kappaB-inducing kinase activity?
Resting state: NIK is held inactive by degradation
In simple terms: In unstimulated cells, NIK is constantly made and constantly destroyed, so it never accumulates enough to signal.
Under basal conditions, a cytosolic complex containing TRAF3, TRAF2 and cIAP1/2 acts as a constitutive E3 ubiquitin ligase module that polyubiquitinates NIK and targets it for proteasomal degradation. This keeps NIK protein levels extremely low and prevents spontaneous non-canonical NF-kappaB activation. The resting state is therefore defined by rapid NIK turnover rather than by an intrinsically inactive kinase fold.
Receptor engagement and release of NIK from the degradation complex
In simple terms: When certain receptors are activated, they pull the degradation machinery away from NIK, letting NIK survive.
Ligand binding to a subset of TNF receptor superfamily members, including LTbetaR, BAFF-R, CD40 and RANK, recruits TRAF3 and the cIAP1/2-TRAF2 module to the receptor, where cIAP1/2 ubiquitinates TRAF3 and triggers its degradation. As TRAF3 is depleted, the NIK degradation complex disassembles, and newly synthesized NIK is no longer destroyed. This receptor-proximal event is the first committed step of GO:0007250.
NIK accumulation and catalytic activation
In simple terms: NIK protein builds up and becomes an active kinase that can phosphorylate its target.
Once protected from degradation, NIK accumulates in the cytoplasm and undergoes activation, including autophosphorylation and conformational changes that enable substrate binding. Activated NIK is the defining output of GO:0007250 and is the form that can phosphorylate downstream substrates. Because NIK activation is coupled to its stabilization, the process integrates protein turnover with catalytic switching.
Phosphorylation of IKKalpha and p100 processing
In simple terms: Active NIK turns on IKKalpha, which trims p100 into p52 so that RelB can enter the nucleus.
Active NIK phosphorylates and activates IKKalpha (CHUK), which in turn phosphorylates the C-terminal region of p100 (NFKB2), leading to partial proteasomal processing of p100 to p52. p52 then dimerizes with RelB and translocates to the nucleus to regulate target genes. This step converts the kinase activation event of GO:0007250 into a transcriptional output.
Feedback and termination of NIK activity
In simple terms: After signaling, NIK is shut off again to avoid uncontrolled inflammation.
NIK activity is self-limiting: newly synthesized TRAF3 and other negative regulators restore the degradation complex, and NIK is again targeted for turnover. This feedback ensures that GO:0007250 is transient under physiological conditions. Loss of this control, for example by TRAF3 mutation or cIAP1/2 loss, leads to constitutive NIK activation and pathological non-canonical NF-kappaB signaling.
Key Genes Involved in GO:0007250 activation of NF-kappaB-inducing kinase activity
The following genes and proteins are the principal components, regulators and effectors of GO:0007250, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAP3K14 (NIK) | Central kinase whose activation defines GO:0007250 | Primary target for KO, point-mutation and overexpression studies [2,4,7] |
| TRAF3 | Scaffold that recruits the NIK degradation complex | Loss causes constitutive NIK activation |
| TRAF2 | Partners with TRAF3 and cIAP1/2 to degrade NIK | Modifier of NIK stability |
| cIAP1/2 (BIRC2/BIRC3) | E3 ligases that ubiquitinate TRAF3 and NIK | Pharmacological and genetic handles on NIK activation |
| CHUK (IKKalpha) | Direct substrate of active NIK | Readout of NIK kinase activity |
| NFKB2 (p100/p52) | Processed by IKKalpha downstream of NIK | Transcriptional effector of the pathway |
| RELB | Dimerization partner of p52 | Nuclear readout of NIK activation |
| LTBR | Receptor that triggers NIK activation | Upstream stimulus for GO:0007250 |
| TNFRSF13C (BAFF-R) | Receptor that activates NIK in B cells | Immune context of NIK activation |
| CD40 | Receptor that activates NIK | Antigen-presenting cell biology |
| TNFRSF11A (RANK) | Receptor that activates NIK in osteoclasts | Bone biology and NIK activation |
| MAP3K14 in beta cells | NIK activation causes beta cell failure | Diabetes modeling with CRISPR |
| MAP3K14 in skeletal muscle | NIK activation provokes insulin resistance | Metabolic disease modeling |
| MAP3K14 in motor neurons | NIK inhibition improves ALS motor performance | Neurodegeneration modeling |
| MAP3K14 in mesenchymal lineage | Constitutive NIK drives soft tissue sarcoma | Cancer modeling with Cre-driven activation |
| MAP3K14 in T cells | NIK maintains metabolic fitness in antitumor immunity | Immunometabolism studies |
| MAP3K14 in innate immune cells | NIK governs mitochondrial respiration and inflammation | Innate immunity and metabolism |
How Is activation of NF-kappaB-inducing kinase activity Regulated?
GO:0007250 is regulated primarily at the level of NIK protein stability. In resting cells, TRAF3, TRAF2 and cIAP1/2 form a degradation complex that continuously ubiquitinates NIK and targets it to the proteasome, keeping the pathway off. Receptor signals from LTbetaR, BAFF-R, CD40 or RANK recruit this complex to the receptor, where cIAP1/2-mediated degradation of TRAF3 dismantles the complex and allows NIK to accumulate and activate. This on/off switch is the principal regulatory layer of the process. Downstream, active NIK phosphorylates IKKalpha, which processes p100 to p52 and enables RelB-p52 nuclear activity. Feedback restoration of TRAF3 and other negative regulators terminates the signal. In disease settings, genetic lesions that remove TRAF3 or cIAP1/2 function produce constitutive NIK activation, illustrating how loss of regulation converts a transient process into a chronic driver [1,2].
activation of NF-kappaB-inducing kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MAP3K14 (NIK) | Soft tissue sarcoma | Mesenchymal Cre-driven NIK activation knock-in mouse |
| MAP3K14 (NIK) | Beta cell failure and diabetes | Beta cell-specific NIK overexpression or knock-in |
| MAP3K14 (NIK) | Insulin resistance in obesity | Skeletal muscle NIK overexpression or KO |
| MAP3K14 (NIK) | Amyotrophic lateral sclerosis | ALS animal model with NIK inhibition or KO |
| MAP3K14 (NIK) | Antitumor immunity and immunometabolism [3,8] | T cell or innate immune cell NIK KO and metabolic assays [3,8] |
Cancer and soft tissue sarcoma
Constitutive activation of NIK in the mesenchymal lineage, achieved with Osterix (Sp7)- or fibroblast-specific protein 1 (S100a4)-Cre drivers, drives spontaneous soft tissue sarcoma in mice, directly linking GO:0007250 to tumorigenesis. NIK is also broadly implicated in cancer biology, where its activation supports survival and proliferation programs. These findings make NIK activation a candidate therapeutic node in mesenchymal and other malignancies [2,7].
Diabetes and insulin resistance
Activation of NIK in islet beta cells causes beta cell failure and diabetes in experimental models, showing that GO:0007250 can directly damage the insulin-secreting compartment. In skeletal muscle of obese mice, NIK provokes insulin resistance, extending the pathological reach of NIK activation to peripheral glucose handling. Together these studies position NIK activation as a mechanistic link between inflammation and metabolic disease [4,5].
Neurodegeneration: amyotrophic lateral sclerosis
Inhibiting NIK improved motor performance in an ALS animal model, indicating that excessive NIK activation contributes to motor neuron dysfunction. This suggests that pharmacological or genetic suppression of GO:0007250 may be beneficial in neurodegenerative contexts.
Immunometabolism and antitumor immunity
NIK maintains T cell metabolic fitness in antitumor immunity, and NIK governs mitochondrial respiratory capacity, differentiation and inflammatory status of innate immune cells [3,8]. These findings show that GO:0007250 is not only a driver of pathology but also a required physiological process for effective immune responses, which has implications for immunotherapy design [3,8].
From activation of NF-kappaB-inducing kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NIK block non-canonical NF-kappaB signaling? | MAP3K14 knockout cell line or mouse |
| Does a specific NIK residue control catalytic activation? | NIK point-mutation knock-in |
| Does constitutive NIK activation drive sarcoma? | Mesenchymal Cre-driven NIK activation knock-in |
| Does NIK activation in beta cells cause diabetes? | Beta cell-specific NIK overexpression or knock-in |
| Can NIK inhibition improve ALS motor performance? | ALS animal model treated with NIK inhibitor or NIK KO |
| Does NIK control immune cell mitochondrial respiration? | NIK KO or overexpression in T cells and innate immune cells [3,8] |
How to Study the activation of NF-kappaB-inducing kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of NIK or regulator function | Testing requirement for GO:0007250 |
| Point-mutation knock-in | Effect of specific NIK residues | Dissecting catalytic vs scaffolding roles |
| RNA-seq | Transcriptional output of RelB-p52 | Downstream readout of NIK activation |
| Immunoblotting for p100/p52 | Processing of NFKB2 | Direct biochemical readout of NIK activity |
| Seahorse metabolic assay | Mitochondrial respiratory capacity | Immunometabolism studies [3,8] |
| Cre-driven activation models | Organ-level consequences of NIK activation | Sarcoma, diabetes, ALS modeling [4,6,7] |
| Pharmacological NIK inhibition | Reversibility of NIK-driven phenotypes | Therapeutic proof-of-concept |
CRISPR knockout and point-mutation screens
CRISPR knockout of MAP3K14 or its regulators (TRAF3, TRAF2, BIRC2/BIRC3) provides a clean way to test whether GO:0007250 is required for a given phenotype. Point-mutation knock-in of catalytic residues or phospho-sites in NIK allows separation of kinase activity from scaffolding functions. These approaches are especially useful in cancer and metabolic models where NIK activation is suspected to be causal [2,4,7].
Transcriptional and proteomic readouts
Because active NIK drives p100 processing to p52 and RelB-p52 target gene expression, RNA-seq and p100/p52 immunoblotting are standard readouts of GO:0007250. Proteomic analysis of NIK-interacting proteins can reveal how the degradation complex is remodeled after receptor engagement. These methods connect the activation event to downstream transcriptional programs.
Metabolic and mitochondrial assays
NIK activation influences mitochondrial respiratory capacity and metabolic fitness of immune cells, so Seahorse extracellular flux analysis and related metabolic assays are informative [3,8]. Combining these assays with NIK KO or overexpression clarifies how GO:0007250 shapes immunometabolism [3,8]. Such experiments are particularly relevant in antitumor immunity studies.
In vivo disease modeling
Cre-driven NIK activation in the mesenchymal lineage, beta cells, skeletal muscle or the nervous system allows researchers to test the causal role of GO:0007250 in sarcoma, diabetes, insulin resistance and ALS [4,5,6,7]. These models can be combined with pharmacological NIK inhibitors to assess therapeutic potential. They provide the strongest evidence linking NIK activation to organism-level phenotypes [4,5,6,7].
How CRISPR Can Be Used to Study GO:0007250 activation of NF-kappaB-inducing kinase activity
Knockout
CRISPR knockout of MAP3K14 is the most direct way to abolish GO:0007250 and test whether a phenotype depends on NIK kinase activation. Knockout of upstream regulators such as TRAF3 or cIAP1/2, by contrast, produces constitutive NIK activation and is used to model pathological pathway engagement. These complementary knockouts are widely applied in cancer and metabolic studies [2,4,7].
Point Mutation
Point-mutation knock-in allows precise interrogation of NIK catalytic residues, autophosphorylation sites or interaction surfaces without deleting the protein. This is critical for distinguishing kinase-dependent from kinase-independent functions of NIK in processes such as immune cell metabolism and inflammation [3,8]. Point mutants also help validate drug-target engagement in NIK inhibitor studies.
Knock-in
Knock-in of constitutively active NIK alleles under tissue-specific Cre drivers has been used to show that NIK activation in the mesenchymal lineage drives soft tissue sarcoma. Similar knock-in strategies can model beta cell failure, insulin resistance or neurodegeneration by activating NIK in the relevant tissue [4,5,6]. These models are essential for establishing causality between GO:0007250 and disease [4,5,6,7].
Overexpression
Overexpression of wild-type or mutant NIK is a rapid way to amplify GO:0007250 in cell lines and to measure downstream p100 processing, RelB nuclear translocation and target gene expression. Overexpression systems are also useful for testing NIK inhibitors and for probing metabolic effects in immune cells [3,8]. When combined with knockout backgrounds, they enable structure-function dissection of the activation process.
How EDITGENE Supports activation of NF-kappaB-inducing kinase activity Research
Researchers studying activation of NF-kappaB-inducing kinase activity-related genes often need to determine whether a candidate gene is causally involved in NIK activation, whether a specific residue controls catalytic switching, or whether forced activation is sufficient to drive a disease phenotype. Answering these questions requires precise, reproducible genome engineering across knockout, point-mutation, knock-in and overexpression formats, ideally paired with library-scale screening and bioinformatic interpretation.
Contact EDITGENE today to design your custom CRISPR model for activation of NF-kappaB-inducing kinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TNFRSF1A Knockout HEK293 Cell Line | EDC90705 | Human | 7132 | Details Get a Quote |
| CARD10 Knockout HEK293 Cell Line | EDJ-KQ545 | Human | 29775 | Details Get a Quote |
| CARD14 Knockout HEK293 Cell Line | EDJ-KQ546 | Human | 79092 | Details Get a Quote |
| LTA Knockout HEK293 Cell Line | EDJ-KQ571 | Human | 4049 | Details Get a Quote |
| LTB Knockout HEK293 Cell Line | EDJ-KQ572 | Human | 4050 | Details Get a Quote |
| LTBR Knockout HEK293 Cell Line | EDJ-KQ573 | Human | 4055 | Details Get a Quote |
| TNFRSF1B Knockout HEK293 Cell Line | EDJ-KQ900 | Human | 7133 | Details Get a Quote |
| TNFRSF10A Knockout HEK293 Cell Line | EDJ-KQ5665 | Human | 8797 | Details Get a Quote |
| TNFRSF10B Knockout HEK293 Cell Line | EDJ-KQ6368 | Human | 8795 | Details Get a Quote |
| TRAF4 Knockout HEK293 Cell Line | EDJ-KQ6659 | Human | 9618 | Details Get a Quote |
| TLR6 Knockout HEK293 Cell Line | EDJ-KQ7010 | Human | 10333 | Details Get a Quote |
| ZFP91 Knockout HEK293 Cell Line | EDJ-KQ9583 | Human | 80829 | Details Get a Quote |
| TLR3 Knockout HEK293 Cell Line | EDJ-KQ15746 | Human | 7098 | Details Get a Quote |
| CARD10 Knockout A-549 Cell Line | EDJ-KQ18919 | Human | 29775 | Details Get a Quote |
| CARD10 Knockout HCT 116 Cell Line | EDJ-KQ18920 | Human | 29775 | Details Get a Quote |
Displaying Records 1 To 15 Of 67 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About activation of NF-kappaB-inducing kinase activity
What is GO:0007250 activation of NF-kappaB-inducing kinase activity?
It is the biological process that switches on the kinase activity of NIK (MAP3K14), the central kinase of the non-canonical NF-kappaB pathway, allowing it to phosphorylate IKKalpha and drive p100 processing to p52.
What genes are involved in activation of NF-kappaB-inducing kinase activity?
The core genes are MAP3K14 (NIK), TRAF3, TRAF2, BIRC2/BIRC3 (cIAP1/2), CHUK (IKKalpha), NFKB2 and RELB, with upstream receptors LTBR, TNFRSF13C, CD40 and TNFRSF11A.
How is NIK activation regulated?
NIK is kept off by a TRAF3-TRAF2-cIAP1/2 degradation complex; receptor engagement dismantles this complex, allowing NIK to accumulate and activate, after which feedback restores the off state.
Why is NIK activation important in cancer?
Constitutive NIK activation in the mesenchymal lineage drives spontaneous soft tissue sarcoma in mice, and NIK is broadly implicated in cancer biology [2,7].
Is NIK activation involved in diabetes?
Yes. Activation of NIK in islet beta cells causes beta cell failure and diabetes, and NIK provokes insulin resistance in skeletal muscle of obese mice [4,5].
What is the link between NIK activation and ALS?
Inhibiting NIK improved motor performance in an ALS animal model, suggesting excessive NIK activation contributes to motor neuron dysfunction.
Does NIK activation affect immune cell metabolism?
Yes. NIK maintains T cell metabolic fitness in antitumor immunity and governs mitochondrial respiratory capacity and inflammatory status of innate immune cells [3,8].
What experimental models are used to study NIK activation?
Common models include MAP3K14 knockout cells, NIK point-mutation knock-ins, tissue-specific Cre-driven NIK activation knock-ins, overexpression lines and pharmacological NIK inhibitors [1,4,6,7].
How can CRISPR help study GO:0007250?
CRISPR knockout removes NIK or its regulators, point-mutation knock-in dissects catalytic residues, knock-in creates constitutive activation, and overexpression amplifies the pathway for readout assays [1,7].
What are the main downstream readouts of NIK activation?
The key readouts are IKKalpha phosphorylation, p100 processing to p52, RelB-p52 nuclear translocation and expression of non-canonical NF-kappaB target genes.
Conclusion
GO:0007250, activation of NF-kappaB-inducing kinase activity, is the committed regulatory step that converts NIK from a rapidly degraded protein into an active kinase capable of driving non-canonical NF-kappaB signaling. Its importance spans cancer, diabetes, insulin resistance, ALS and immunometabolism, with constitutive NIK activation causing soft tissue sarcoma and beta cell failure in model systems [4,7]. Because the process is controlled by a well-defined degradation complex and feeds into measurable downstream events such as p100 processing, it is highly amenable to CRISPR-based dissection. Researchers can now combine knockout, point-mutation, knock-in and overexpression models with transcriptional, proteomic and metabolic readouts to define precisely how NIK activation contributes to a given phenotype [2,3,8]. Such work is likely to clarify which diseases will benefit from therapeutic inhibition of NIK activation and which require preservation of its physiological immune functions [3,6,8].
References
- 1. Sun SC. 2011. Non-canonical NF-κB signaling pathway.. Cell Res 21(1):71-85 PMID: 21173796
- 2. Maubach G et al.. 2019. NF-kappaB-inducing kinase in cancer.. Biochim Biophys Acta Rev Cancer 1871(1):40-49 PMID: 30419317
- 3. Gu M et al.. 2021. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity.. Nat Immunol 22(2):193-204 PMID: 33398181
- 4. Li X et al.. 2020. Activation of NF-κB-Inducing Kinase in Islet β Cells Causes β Cell Failure and Diabetes.. Mol Ther 28(11):2430-2441 PMID: 32730745
- 5. Chen X et al.. 2023. NF-κB-Inducing Kinase Provokes Insulin Resistance in Skeletal Muscle of Obese Mice.. Inflammation 46(4):1445-1457 PMID: 37171694
- 6. Cao M et al.. 2024. Inhibiting NF-κB inducing kinase improved the motor performance of ALS animal model.. Brain Res 1843:149124 PMID: 39019135
- 7. Davis JL et al.. 2021. Constitutive activation of NF-κB inducing kinase (NIK) in the mesenchymal lineage using Osterix (Sp7)- or Fibroblast-specific protein 1 (S100a4)-Cre drives spontaneous soft tissue sarcoma.. PLoS One 16(7):e0254426 PMID: 34292968
- 8. Keeney JN et al.. 2023. NF-κB-Inducing Kinase Governs the Mitochondrial Respiratory Capacity, Differentiation, and Inflammatory Status of Innate Immune Cells.. J Immunol 210(8):1123-1133 PMID: 36881877
